多発性嚢胞腎市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療タイプ別、エンドユーザー別、地域別、競合別、2020-2030年

多発性嚢胞腎（PKD）の世界市場は、2024年に5億239万米ドルと評価され、予測期間中にCAGR 7.11％で成長し、2030年には7億5,869万米ドルに達すると予測されています。

PKDは、腎臓に液体が充満した嚢胞が増殖し、進行性の腎肥大と最終的な腎不全に至ることを特徴とする遺伝的疾患です。常染色体優性遺伝と劣性遺伝の両方のPKDの世界の有病率の上昇、診断能力の向上、研究投資の増加が市場の拡大を後押ししています。プレシジョン・メディシンの進歩により、個々の遺伝子プロファイルに基づいたより的を絞った治療アプローチが可能となっています。患者数の増加は、ヘルスケア専門家の意識の高まりや早期発見のための遺伝子スクリーニングの統合と相まって、効果的な治療オプションに対する需要を刺激しています。製薬企業や研究機関は、疾患の進行を遅らせ、患者の転帰を改善するための革新的な治療法の開発にますます注力しており、市場の成長に拍車をかけています。

市場促進要因

多発性嚢胞腎（PKD）の有病率の増加

主な市場課題

高い治療費

主要市場動向

遺伝子調査の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の多発性嚢胞腎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 型別（常染色体優性多発性嚢胞腎（ADPKD）、常染色体劣性多発性嚢胞腎（ARPKD）、その他）
  • 治療の種類別（診断、薬物療法）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • タイプ別
  • 治療の種類別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の多発性嚢胞腎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療の種類別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の多発性嚢胞腎市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の多発性嚢胞腎市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の多発性嚢胞腎市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの多発性嚢胞腎市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の鉄欠乏性貧血： SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Otsuka Pharmaceuticals
• Camber Pharmaceuticals
• Apotex Corp
• Ascend Laboratories
• Par Pharmaceuticals
• Teva Pharmaceutical Industries
• Merck KGA
• Accord Healthcare
• Pfizer Inc.
• PD-Rx Pharmaceuticals, Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Polycystic Kidney Disease (PKD) Market was valued at USD 502.39 million in 2024 and is projected to reach USD 758.69 million by 2030, growing at a CAGR of 7.11% during the forecast period. PKD is a genetic condition characterized by the growth of fluid-filled cysts in the kidneys, leading to progressive kidney enlargement and eventual renal failure. Market expansion is being propelled by a rising global prevalence of both autosomal dominant and recessive forms of PKD, improved diagnostic capabilities, and increased research investment. Advancements in precision medicine are enabling more targeted therapeutic approaches based on individual genetic profiles. The growing patient population, combined with heightened awareness among healthcare professionals and the integration of genetic screening for early detection, has stimulated demand for effective treatment options. Pharmaceutical companies and research institutions are increasingly focused on developing innovative interventions to delay disease progression and enhance patient outcomes, thereby fueling market growth.

Key Market Drivers

Increasing Prevalence of Polycystic Kidney Disease (PKD)

The rising incidence of PKD worldwide is a major growth catalyst for the market. As a hereditary condition, PKD has seen growing diagnosis rates due to enhanced screening and genetic testing. Autosomal dominant PKD (ADPKD) affects approximately 1 in every 400 to 1,000 people, while autosomal recessive PKD (ARPKD) occurs in 1 in 20,000 to 40,000 individuals. With healthcare systems adopting more robust diagnostic practices, particularly among individuals with a family history of the disease, the patient pool is expanding. Increased awareness among clinicians and the general public has led to earlier detection and intervention, promoting demand for both supportive and disease-modifying therapies. As the affected population grows, pharmaceutical investment in PKD-focused research and treatment innovation is also accelerating.

Key Market Challenges

High Treatment Costs

The high cost associated with PKD treatment continues to hinder broader access and adoption of advanced therapies. Management of PKD often requires lifelong monitoring, imaging, nephrology consultations, and eventually renal replacement therapies such as dialysis or kidney transplantation in advanced cases. Limited availability of approved and cost-effective medications further compounds the financial burden on patients. Targeted drugs that are in clinical development or recently approved tend to be expensive, making them inaccessible to many, particularly in low-resource settings. Additionally, the long-term costs of managing disease progression and complications place pressure on both patients and healthcare systems, posing a substantial challenge to the market's growth and equitable treatment access.

Key Market Trends

Advancements in Genetic Research

Ongoing progress in genetic research is significantly influencing the PKD treatment landscape. Identification of mutations in genes such as PKD1 and PKD2 has facilitated the development of personalized treatment strategies and innovative therapies targeting the molecular mechanisms driving cyst formation. Gene-editing technologies and pharmacogenomics are enabling the design of more effective and potentially curative interventions. Furthermore, the discovery of reliable biomarkers is supporting early diagnosis, disease monitoring, and patient stratification for clinical trials. These advancements are streamlining drug development and paving the way for precision medicine in PKD care. Collaborations among geneticists, pharmaceutical companies, and advocacy groups are accelerating these efforts, increasing the pace at which research translates into clinical practice and market offerings.

Key Market Players

• Otsuka Pharmaceuticals
• Camber Pharmaceuticals
• Apotex Corp
• Ascend Laboratories
• Par Pharmaceuticals
• Teva Pharmaceutical Industries
• Merck KGA
• Accord Healthcare
• Pfizer Inc.
• PD-Rx Pharmaceuticals, Inc

Report Scope:

In this report, the Global Polycystic Kidney Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Polycystic Kidney Disease Market, By Type:

• Autosomal dominant polycystic kidney disease (ADPKD)
• Autosomal recessive polycystic kidney disease (ARPKD)
• Others

Global Polycystic Kidney Disease Market, By Treatment Type:

• Diagnosis
• Drug/Therapy

Global Polycystic Kidney Disease Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Global Polycystic Kidney Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polycystic Kidney Disease Market.

Available Customizations:

Global Polycystic Kidney Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Polycystic Kidney Disease Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Autosomal dominant polycystic kidney disease (ADPKD), Autosomal recessive polycystic kidney disease (ARPKD), Others)
  • 4.2.2. By Treatment Type (Diagnosis, Drug/Therapy)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Treatment Type
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Polycystic Kidney Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment Type
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Polycystic Kidney Disease Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Treatment Type
      • 5.3.1.2.3. By End User
  • 5.3.2. India Polycystic Kidney Disease Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Treatment Type
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Polycystic Kidney Disease Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Treatment Type
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Polycystic Kidney Disease Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Treatment Type
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Polycystic Kidney Disease Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Treatment Type
      • 5.3.5.2.3. By End User

6. Europe Polycystic Kidney Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Polycystic Kidney Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Polycystic Kidney Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Polycystic Kidney Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Polycystic Kidney Disease Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatment Type
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Polycystic Kidney Disease Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatment Type
      • 6.3.5.2.3. By End User

7. North America Polycystic Kidney Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Polycystic Kidney Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Polycystic Kidney Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Polycystic Kidney Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End User

8. South America Polycystic Kidney Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Polycystic Kidney Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Polycystic Kidney Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Polycystic Kidney Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End User

9. Middle East and Africa Polycystic Kidney Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Polycystic Kidney Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Polycystic Kidney Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Polycystic Kidney Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Otsuka Pharmaceuticals
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Camber Pharmaceuticals
• 14.3. Apotex Corp
• 14.4. Ascend Laboratories
• 14.5. Par Pharmaceuticals
• 14.6. Teva Pharmaceutical Industries
• 14.7. Merck KGA
• 14.8. Accord Healthcare
• 14.9. Pfizer Inc.
• 14.10. PD-Rx Pharmaceuticals, Inc

15. Strategic Recommendations

16. About Us & Disclaimer